

**BIOGRAPHICAL SKETCH**

Provide the following information for the key personnel in the order listed for Form Page 2.  
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME		POSITION TITLE	
Richard Dubinsky, MD		Associate Professor of Neurology	
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)			
INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
University of Missouri - Kansas City 6 year BA/MD program	BA	1981	Biology and History
University of Missouri - Kansas City 6 year BA/MD program	MD	1982	Medicine

**A. Positions and Honors:**

1982-83	Internship in Internal Medicine, Baylor College of Medicine, Houston, Texas
1983-86	Residency in Neurology, Baylor College of Medicine, Houston, Texas
1986	Award for Outstanding Resident in Neurology
1986-88	Fellowship in Human Motor Control under Dr. Mark Hallett. Human Motor Control Laboratory, Medical Neurology Branch, National Institute of neurological, Communicative Disorders and Stroke, National Institutes of Health, Bethesda, Maryland.
July, 1988 – June, 1992	Assistant Professor of Neurology, Department of Neurology, School of Medicine, University of Kansas Medical Center, Kansas City, Kansas
Sept. 1991 to June, 1997	Director, Electromyography Laboratory, Department of Neurology, School of Medicine, University of Kansas Medical Center
July, 1992 – present	Associate Professor of Neurology, Department of Neurology, School of Medicine, University of Kansas Medical Center
July, 1992 – June, 1997	Director, Residency Program, Department of Neurology, School of Medicine, University of Kansas Medical Center
July, 1997 – present	Member, Quality Standards Subcommittee of the American Academy of Neurology
January 2001 – present	Director, Electromyography Laboratory, University of Kansas Medical Center
September 2001 – present	Workgroup Chair, End of Life in Huntington's Disease Project, sponsored by the Robert Woods Johnson Foundation
July 2001 – present	Associate director, clinical neurophysiology fellowship program at the University of Kansas Medical Center
July 2001 – present	EMG laboratory director, Department of Neurology, University of Kansas Medical Center

**B. Selected peer-reviewed publications (in chronological order).** Do not include publications submitted or in preparation.

**Dubinsky RM**, Carolyn Gray, Debra Husted, Karen Busenbark, David Parrish, David Wiltfong, William C. Koller. Driving in Parkinson's Disease. *Neurology* 1991;41:517-519

Paulsen J, and the Huntington Study Group. The clinical utility of the Stroop test A in a multicenter study of Huntington's disease. *J Intl Neuropsychol Society*. 1996;2:35

**Dubinsky RM**, Dubinsky JS, Stein ACS. The effects of phenytoin on driving performance on well controlled epileptics. Second International Conference on Fatigue and Transportation. Freemantle, WA. 1996

**Dubinsky RM**, Stein AC, Lyons K. Practice Parameter: Driving in Patients with Alzheimer's disease. Report of the Quality Standards Subcommittee. Neurology, 2000;54:2205-2211

Practice Advisory: The use of felbamate in the treatment of patients with intractable epilepsy. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1999;52:1540-45.

R. S. Doody, C. Beck, J. Cummings, S. DeKosky, **R. Dubinsky**, L. Gwyther, J. Kaye, R. Mohs, J. Stevens, L. Thal, P. Whitehouse. Practice Parameter: Management of Dementia (An Evidence-Based Review) Report of the Quality Standards Subcommittee of The American Academy of Neurology Neurology 2001;56:1154-66

D. Knopman, J. Cummings, S. DeKosky, et. al. Practice Parameter: Diagnosis of Dementia(An Evidence-Based Review)Report of the Quality Standards Subcommittee of The American Academy of Neurology. Neurology 2001;56:1143-53. (multi-authored paper)

R.C. Petersen, PhD, MD; J.C. Stevens, MD; M. Ganguli, MD, MPH; E.G. Tangalos, MD; J.L. Cummings, MD; and S.T. DeKosky, MD Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology, Neurology 2001;56:1133-1142

**Dubinsky RM**, Tyler D, Perera S, Duncan P, Lai S-M. Driving After Stroke: Effects of Severity and Advice on Driving. Neurology 2001;56 (Suppl. P03.006)

Brin MF, Lyons KE, Doucette J, Adler CH, Caviness JN, Comella CL, **Dubinsky RM**, Friedman JH, Manyam BV, Matsumoto JY, Pullman SL, Rajput AH, Sethi KD, Tanner C, Koller WC.A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology 2001 Jun 12;56(11):1523-8

Kieburtz K and the Huntington Study Group. A Randomized, Placebo-Controlled Trial of Coenzyme Q<sub>10</sub> and Remacemide in Huntington's Disease (CARE-HE). Neurology 2001;57:397-404

Jablecki CK, Andary MT, Fleoter MK, Miller RG, Quartly CA, Vennix MJ and Wilson JR. Practice Parameter: Electrodiagnostic studies in carpal tunnel syndrome. Report of the American Association of Electrodiagnostic Medicine, American Academy of Neurology, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2002;58:1589-1592 (multi-authored paper)

Ment LR, Bada HS, Barnes P, Grant PE, Hirtz D, Papile LA, Pinto-Martin J, Rivkin M, Slovis TL. Practice Parameter: Neuroimaging of the neonate. Report of the Quality Standards Subcommittee of the American Academy of Neurology and The Practice Committee of the Child Neurology Society. Neurology 2002;58:1726-1738 (multi-authored paper)

Lewis DW, Ashwal S, Dahl G, Dorbab D, Hirtz D, Prensky A, Jarjour I. Practice Parameter: Evaluations of children and Adolescents with recurrent headaches. Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2002;59:490-498 (multi-authored paper)

Dejousse L, Knowlton B, Cupples LA, Marder K, Shouson I, Meyers RH, and the Huntington Study Group. Weight loss in Early stage of Huntington's disease. Neurology 2002;59:1325-1330 (multi-authored paper)

Chang BS, Lowenstein DH. Practice Parameter: Antiepileptic drug prophylaxis in severe traumatic brain injury. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003;60:10-16 (multi-authored paper)

Hirtz D, Berg A, Bertis D, Camfield C, Camfield P, Crumrine P, Galliard WD, Schneider S, Shinnar S. Practice Parameter: Treatment of the child with a first unprovoked seizure. Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2003;60:166-175 (multi-authored paper)

Engel J, Wiebe S, French J et al. Practice Parameter: Temporal lobe and localized neocortical resections for epilepsy. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003;60:538-547 (multi-authored paper)

**C. Research Support.** List selected ongoing or completed (during the last three years) research projects (federal and non-federal support). Begin with the projects that are most relevant to the research proposed in this application. Briefly indicate the overall goals of the projects and responsibilities of principal investigator identified above.

**Dubinsky, RM.**Previous

- |  |                                   |                         |
|--|-----------------------------------|-------------------------|
| 1. 1 – R01 NS 35284-01 (Kiebertz)<br>NIH/NINDS<br>Co-Enzyme Q <sub>10</sub> and Remacemide: Evaluation in HD<br>The major goal of this project is to determine if the progression of Huntington's disease can be slowed through the use of medications that affect oxygen metabolism in the mitochondria of the basal ganglia. | 11/1/96 - 10/31/00<br>\$1,659,392 | 5%, site investigator   |
| 2. Food and Drug Administration, (Marshall)<br>Orphan Drug Research Grant,<br><b>Riluzol Dosing in Huntington's Disease (RDI-HD).</b><br>The major goal of this study was to determine the safety of Riluzol in the treatment of chorea in those with Huntington's disease   | 1/2000 - 4/2000                   | 5% blinded investigator |
| 3. Astra-Zeneca.<br>Open label extension study of remacemide in Huntington's disease ( <b>248</b> )<br>The major goal of this extension of CARE-HD was to gather additional safety information on remacemide in the treatment of those with Huntington's disease.  | 6/2000 - 7/2001                   | 5% site investigator    |

Current:

- |  |                            |     |
|--|----------------------------|-----|
| (Paulsen)<br>NIH<br>PREDICT-HD<br>A prospective observational study to prospectively determine, in a double-blinded controlled fashion, the rate of illness onset (phenoconversion) in individuals who are at risk for HD<br>Overlap: None   | 9/1/01-8/31/04<br>\$31,250 | 5%  |
| 1R01HG02449-01 (Shoulson)<br>NIH/NHGRI/NINDS<br>Prospective Huntington At Risk Observational Study (PHAROS)<br>A prospective observational study to prospectively determine, in a double-blinded controlled fashion, the rate of illness onset (phenoconversion) in individuals who are at immediate risk for inheriting the HD gene and who are Unaware and wish to remain unaware of their HD gene status<br>Overlap: None | 7/1/02-6/30/06<br>\$22,950 | 5%  |
| RI 2003 (Dubinsky)<br>Research Institute, University of Kansas<br>Phase I tolerability study of cysteamine in Huntington's disease (CYT-I)<br>An open-label dose escalation study of cysteamine to determine the maximally tolerated dose<br>Overlap: None   | 4/1/03-3/31/04<br>\$35,000 | 10% |
| Elan Pharmaceuticals<br>Phase IV, post marketing surveillance study of Myobloc in the treatment of cervical dystonia to determine the Development rate of resistance<br>Overlap: None  | 3/1/02-2/28/06<br>\$18,000 | 5%  |